A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...

Dan was a writer on CNET's How-To and Thought Leadership teams. His byline has appeared in The New York Times, Newsweek, NBC News, Architectural Digest and elsewhere. He is a crossword junkie and is ...

Amber Hill spent 14 years as a medical researcher. She didn’t mind the work, but there was one thing she consistently hated: administrative tasks. “I think most people do, especially in research,” she ...

Frank David was just starting an independent research program on cell signaling in cancer and kidney development at a lab in Boston when he realized he’d rather be doing something else. “I figured out ...

When people hear the term “clinical trial,” they often imagine someone with a serious illness, desperate for a last-resort treatment, being poked and prodded in a lab. These images are persistent, but ...

When the Trump administration brutally cut federal funding for biomedical research earlier this year, at least 383 clinical trials that were already in progress were abruptly canceled, cutting off ...

In this Q&A, John Kirk, principal regulatory specialist at Veristat, explains how the FDA’s Commissioner’s National Priority ...

Congressional Democrats are demanding answers after a new report detailed disruptions to cancer clinical trials and other veterans’ services. See the story in the video aboveAccording to a ProPublica ...

Digit health technologies (DHT) are a key aspect of U.S. Health & Human Services (HHS) Secretary Robert F. Kennedy Jr.’s Make America Healthy ...

The FDA has cleared Neurosense to begin its pivotal Phase 3 clinical trial of PrimeC for the treatment of amyotrophic lateral ...